Medipostco메디포스트

Medipostco is still loss-making on trailing numbers, and its shares have fallen about 41% over the past year.

Medipostco, a Seongnam-based biotech known for its Celltree cord blood business and the Cartistem knee therapy, reported trailing revenue of about ₩74.8B to H1 2026 but an operating loss of about ₩76.5B. The company has ₩78.4B in cash against ₩158.4B in borrowings, and its shares closed at ₩8,470 with a market value of about ₩332B. The data does not include a profit forecast or any analyst view.

What stands out

• Trailing operating margin is -102.2% and net margin is -30.8%, so losses are large relative to sales.
• Revenue has grown modestly from ₩54.9B in 2021 to ₩73.7B in 2025, but operating losses widened from ₩5.2B to ₩68.0B over the same period.
• Liabilities are 104.2% of equity, and free cash flow over the trailing period was negative at about -₩62.7B.
• Book value multiple (P/B) is 1.2 and there is no meaningful earnings multiple because the company is loss-making; the dividend yield is 0%.
• Foreign ownership fell from 3.1% to 2.5% over about 60 days, and the 20-day investor flows show small net selling by foreigners and retail investors offset by institutions.

What to watch

• The shareholders' meeting and proxy documents filed in September and October 2026, which may include agenda items the data does not describe.
• Repeated 'Adjustment of Conversion Price' filings in June and July 2026, which relate to convertible securities and could affect share count.
• The next quarterly or annual report, to see whether operating losses narrow from the current trailing level.